• Company
• Immunotherapy shows effect as first-line treatment for BTC
• by Dec 8, 2022 06:05am

• Product
• MFDS' statement of consent to Rx of the active ingredients
• by Kang, Shin-Kook Dec 7, 2022 05:55am

• Policy
• Only K-CAB continues to be applied refund-type PVA
• by Lee, Tak-Sun Dec 7, 2022 05:55am

• Policy
• Vaccine sales reached 3.4178 trillion won in Korea last year
• by Lee, Hye-Kyung Dec 7, 2022 05:55am

• Policy
• Reimb of antidiabetic SGLT-2+DPP-4 combo near
• by Kim, Jung-Ju Dec 7, 2022 05:55am

• Company
• Oral Exon20 targeted Exkivity to apply for reimb in Korea
• by Eo, Yun-Ho Dec 6, 2022 07:55pm

• Policy
• One-shot Zolgensma fulfills terms of its RSA contract
• by Kim, Jung-Ju Dec 6, 2022 05:57am

• Company
• ImmuneOncia targets niche market in cancer immunotherapy
• by Dec 6, 2022 05:57am

• Company
• Concerns over Leclaza's sluggish secondary indicators
• by Dec 6, 2022 05:57am

• Policy
• The government is conducting six studies on drug prices
• by Kim, Jung-Ju Dec 6, 2022 05:57am